Business
Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting
BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company
About this update from Enliven Therapeutics, Inc.
[{"type":"text","content":"BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.\nPoster Presentation Details \nAbstract 4712 – ELVN-002, a potent, selective HER2 inhibitor with a differentiated binding mode conferring the potential for enhanced efficacy in combination with HER2-targeting antibody-drug conjugates Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDTSession: Targeted Therapies and Combinations 2Location: Poster Section 34\nAbstract 4361 – Development and application of a mechanistic pharmacokinetic pharmacodynamic (PKPD) model to predict anti-chronic myeloid leukemia (CML) effects of tyrosine kinase inhibitorsDate/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDTSession: Pharmacokinetics and Pharmacodynamics of Cancer TherapeuticsLocation: Poster Section 20\nAbstract LB295 – ELV-3111, a type 1 pan-RAF inhibitor, that safely combines with MEK inhibitors for enhanced anti-tumor activity in NRAS and BRAF mutant cancers including the most common mechanisms of BRAF inhibitor clinical resistanceDate/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDTSession: Late-Breaking Research: Experimental and Molecular Therapeutics 3Location: Poster Section 52\nAbstract LB294 – Mechanism of tumor-selective inhibition of dimeric RAF by a Type 1 RAF inhibitorDate/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDTSession: Late-Breaking Research: Experimental and Molecular Therapeutics 3Location: Poster Section 52\nAbstract 5515 – ELVN-001, a highly selective ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia alone or in combination with asciminibDate/Time: Tuesday, April 29, 2025, 2:00 p.m. – 5:00 p.m. CDTSession: Drug Resistance in Molecular Targeted Therapies 3Location: Poster Section 17\nAbstracts are currently available on the AACR website. Following the presentations, copies will be available on the \"Program Presentations & Publications\" section of the Company's website at www.enliventherapeutics.com.\nAbout Enliven Therapeu...